Tsukasa Matsubara

5.3k total citations
105 papers, 2.8k citations indexed

About

Tsukasa Matsubara is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Tsukasa Matsubara has authored 105 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Rheumatology, 26 papers in Hematology and 21 papers in Genetics. Recurrent topics in Tsukasa Matsubara's work include Rheumatoid Arthritis Research and Therapies (58 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Lymphoma Diagnosis and Treatment (20 papers). Tsukasa Matsubara is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (58 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Lymphoma Diagnosis and Treatment (20 papers). Tsukasa Matsubara collaborates with scholars based in Japan, United States and United Kingdom. Tsukasa Matsubara's co-authors include M Ziff, K Hirohata, Morris Ziff, Kozo Kaibuchi, Yoshimi Takai, Yasutomi Nishizuka, Nobuyuki Miyasaka, Tsutomu Takeuchi, Soichiro Hirata and Hisashi Yamanaka and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Immunology and PLoS ONE.

In The Last Decade

Tsukasa Matsubara

101 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tsukasa Matsubara Japan	30	1.1k	618	583	472	420	105	2.8k
C. López-Pedrera Spain	34	1.3k 1.2×	1.2k 1.9×	965 1.7×	732 1.6×	271 0.6×	126	3.4k
Keiju Hiromura Japan	29	685 0.6×	1.1k 1.8×	866 1.5×	215 0.5×	246 0.6×	123	3.4k
Yoriaki Kaneko Japan	26	417 0.4×	529 0.9×	1.3k 2.3×	362 0.8×	256 0.6×	91	2.6k
Ping Zhu China	34	1.2k 1.0×	1.4k 2.3×	1.8k 3.0×	380 0.8×	231 0.6×	142	3.7k
Pankaj Gupta India	21	495 0.4×	617 1.0×	1000 1.7×	313 0.7×	95 0.2×	75	2.6k
Olivier Harari United Kingdom	20	571 0.5×	428 0.7×	839 1.4×	243 0.5×	133 0.3×	37	1.9k
Monika Biniecka Ireland	23	849 0.8×	952 1.5×	672 1.2×	345 0.7×	125 0.3×	42	2.4k
Catherine Meyer‐Schwesinger Germany	37	359 0.3×	1.3k 2.1×	1.3k 2.2×	260 0.6×	312 0.7×	93	4.6k
Changli Wei United States	27	273 0.2×	1.2k 2.0×	651 1.1×	276 0.6×	313 0.7×	61	4.2k
Fabiola Terzi France	35	310 0.3×	1.7k 2.8×	359 0.6×	197 0.4×	509 1.2×	93	3.9k

Countries citing papers authored by Tsukasa Matsubara

Since Specialization

Citations

This map shows the geographic impact of Tsukasa Matsubara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsukasa Matsubara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsukasa Matsubara more than expected).

Fields of papers citing papers by Tsukasa Matsubara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsukasa Matsubara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsukasa Matsubara. The network helps show where Tsukasa Matsubara may publish in the future.

Co-authorship network of co-authors of Tsukasa Matsubara

This figure shows the co-authorship network connecting the top 25 collaborators of Tsukasa Matsubara. A scholar is included among the top collaborators of Tsukasa Matsubara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsukasa Matsubara. Tsukasa Matsubara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Yoshihito, Shinya Hayashi, Tomoyuki Kamenaga, et al.. (2025). Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNFα-stimulated fibroblast-like synoviocytes derived from patients with RA. Scientific Reports. 15(1). 9736–9736. 3 indexed citations

Tsubosaka, Masanori, Tomoyuki Kamenaga, Yuichi Kuroda, et al.. (2025). High MDR1 expression in RA is associated with increased MMP-3 levels and use of bDMARDs: potential independence of JAK inhibitors from MDR1. Lara D. Veeken. 65(2).

Saraux, Alain, et al.. (2024). Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries. Rheumatology and Therapy. 11(2). 257–268.

Hayashi, Shinya, Yoshihito Suda, Masanori Tsubosaka, et al.. (2024). JAK inhibitors inhibit angiogenesis by reducing VEGF production from rheumatoid arthritis–derived fibroblast-like synoviocytes. Clinical Rheumatology. 43(11). 3525–3536. 6 indexed citations

Matsubara, Tsukasa, Kou Katayama, Akira Sagawa, et al.. (2023). Investigation of treatment continuity, usefulness, and nocebo effect in switching from the original etanercept to its biosimilar in patients with rheumatoid arthritis: A JET observational study in Japanese clinical practice. Modern Rheumatology. 34(2). 307–312. 1 indexed citations

Ito, Hiromu, Shigeyoshi Tsuji, Yuichi Mochida, et al.. (2019). Does Abatacept Increase Postoperative Adverse Events in Rheumatoid Arthritis Compared with Conventional Synthetic Disease-modifying Drugs?. The Journal of Rheumatology. 47(4). 502–509. 9 indexed citations

Matsubara, Tsukasa, Hiroshi Inoue, Toshihiro Nakajima, et al.. (2018). Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD Open. 4(2). e000813–e000813. 10 indexed citations

Atsumi, Tatsuya, Yoshiya Tanaka, Kazuhiko Yamamoto, et al.. (2017). Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases. 76(8). 1348–1356. 30 indexed citations

Atsumi, Tatsuya, Kazuhiko Yamamoto, Tsutomu Takeuchi, et al.. (2015). The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases. 75(1). 75–83. 84 indexed citations

10.

Takeuchi, Tsutomu, Tsukasa Matsubara, Yukitomo Urata, et al.. (2014). Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. Modern Rheumatology. 24(5). 744–753. 11 indexed citations

11.

Yamanaka, Hisashi, Naoko Ishiguro, Tsutomu Takeuchi, et al.. (2014). Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Lara D. Veeken. 53(5). 904–913. 25 indexed citations

12.

Amano, Koichi, Tsukasa Matsubara, Hiroshi Inoue, et al.. (2013). FRI0249 Long-term safety and efficacy of treatment with subcutaneous abatacept in japanese patients with ra who were mtx inadequate responders – 76-week results. Annals of the Rheumatic Diseases. 72. A458–A458. 2 indexed citations

13.

Takeuchi, Tsutomu, Tsukasa Matsubara, Eiichi Suematsu, et al.. (2012). Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Modern Rheumatology. 23(2). 226–235. 24 indexed citations

14.

Matsubara, Tsukasa, et al.. (2012). STUDY ON PROMOTING FACTOR OF ELECTRIC VEHICLE WITH SOCIAL CONFORMITY IN CHOICE SET FORMING AND CHOICE STEP. Journal of Japan Society of Civil Engineers Ser D3 (Infrastructure Planning and Management). 68(5). I_691–I_699. 1 indexed citations

15.

Harigai, Masayoshi, Tsutomu Takeuchi, Yoshiya Tanaka, et al.. (2012). Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology. 22(6). 814–822. 29 indexed citations

16.

Khor, Chiea Chuen, Sonia Dávila, Chisato Shimizu, et al.. (2011). Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. Journal of Medical Genetics. 48(7). 467–472. 42 indexed citations

17.

Yurube, Takashi, Masatoshi Sumi, Kotaro Nishida, et al.. (2010). Progression of Cervical Spine Instabilities in Rheumatoid Arthritis. Spine. 36(8). 647–653. 41 indexed citations

18.

Hasunuma, Tomoko, Toshihiro Nakajima, Hiroyuki Aono, et al.. (1994). Establishment and Characterization of Synovial Cell Clones with Integrated Human T-Cell Leukemia Virus Type-I. Clinical Immunology and Immunopathology. 72(1). 90–97. 16 indexed citations

19.

Matsubara, Tsukasa, et al.. (1991). Enhancement of new bone formation by hematoma at fracture site.. PubMed. 65(5). 349–58. 4 indexed citations

20.

Iguchi, Tetsuhiro, et al.. (1990). Clinical and Histologic Observations of Monoarthritis. Clinical Orthopaedics and Related Research. 250(250). 241–249. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact